GO:0048245 eosinophil chemotaxis: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048245 eosinophil chemotaxis is defined as the movement of an eosinophil in response to an external stimulus.
• Eosinophil chemotaxis is a multistep process involving chemoattractant sensing, adhesion, cytoskeletal rearrangement, and directed migration.
• Key chemoattractants include eotaxin/CCL11, CCL24, CCL26, and complement-derived factors such as C5a.
• Receptors such as CCR3, CD300 family members, and heparan sulfate proteoglycans regulate eosinophil recruitment.
• Dysregulated eosinophil chemotaxis contributes to allergic diseases, eosinophilic skin disorders, and chronic rhinosinusitis with nasal polyps.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of genes controlling eosinophil chemotaxis.
Description
Eosinophil chemotaxis (GO:0048245) is the directed movement of eosinophils along chemical gradients toward sites of inflammation or infection. This process is central to eosinophil biology because it determines where these granulocytes accumulate and exert their effector functions. The QuickGO definition specifies that eosinophil chemotaxis is the movement of an eosinophil in response to an external stimulus, encompassing both random and directed migration components. Researchers study this process to understand allergic inflammation, host defense against parasites, and tissue remodeling. The chemotactic response requires coordinated activation of chemoattractant receptors, integrins, and cytoskeletal machinery. Dysregulation of eosinophil chemotaxis is a hallmark of eosinophilic disorders, including atopic dermatitis, eosinophilic esophagitis, and nasal polyposis. Consequently, genes and pathways controlling eosinophil chemotaxis are attractive targets for therapeutic intervention. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0048245, its molecular players, disease relevance, and experimental models for investigation.
eosinophil chemotaxis At A Glance
| GO ID | GO:0048245 |
|---|---|
| GO term | eosinophil chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Definition | The movement of an eosinophil in response to an external stimulus. |
| Major function | Directed recruitment of eosinophils to sites of inflammation, infection, or tissue damage. |
| Key chemoattractants | CCL11 (eotaxin-1), CCL24 (eotaxin-2), CCL26 (eotaxin-3), C5a, and leukotriene B4. |
| Key receptors | CCR3, CD300 family receptors, and heparan sulfate proteoglycans. |
| Disease relevance | Allergic inflammation, eosinophilic skin diseases, chronic rhinosinusitis with nasal polyps. |
What Is GO:0048245?
Eosinophil chemotaxis (GO:0048245) is the biological process by which an eosinophil moves in response to an external chemical stimulus. This includes both directed migration along a chemoattractant gradient and stimulus-triggered motility changes. The term is a child of leukocyte chemotaxis and is specific to eosinophils, distinguishing it from general cell migration.
Why Is eosinophil chemotaxis Important in Cell Biology?
Eosinophil chemotaxis is critical for understanding how eosinophils are recruited to tissues during allergic inflammation, parasitic infection, and other immune responses. The process determines the spatial distribution of eosinophils and their subsequent effector functions, including degranulation and cytokine release. Because eosinophil accumulation is a hallmark of numerous diseases, targeting chemotaxis pathways offers therapeutic potential. Moreover, chemotaxis assays are standard tools for evaluating eosinophil function in vitro and in vivo.
• Eosinophil chemotaxis is a key step in allergic inflammation and asthma pathogenesis.
• It mediates eosinophil recruitment to the skin in eosinophilic dermatoses.
• Chemotaxis contributes to chronic rhinosinusitis with nasal polyps, where CCL26 and glycolysis play a role.
• Heparan sulfate modulates CCL26-induced eosinophil chemotaxis, highlighting extracellular matrix regulation.
• CD300 family receptors regulate eosinophil survival, chemotaxis, and effector functions.
• Complement system components, such as C5a, are classical eosinophil chemoattractants.
• Eosinophil chemotaxis is essential for host defense against helminth infections.
• Inhibiting eosinophil chemotaxis is a therapeutic strategy for eosinophilic disorders.
• Chemotaxis assays are used to screen anti-inflammatory compounds.
• Understanding chemotaxis mechanisms informs development of targeted biologics and small molecules.
What Happens During eosinophil chemotaxis?
Chemoattractant sensing and receptor activation
In simple terms: Eosinophils detect chemical signals released by other cells.
Eosinophil chemotaxis begins when chemoattractants such as CCL11, CCL24, CCL26, or C5a bind to specific G-protein-coupled receptors on the eosinophil surface. This binding activates intracellular signaling cascades, including phosphatidylinositol 3-kinase and Rho GTPase pathways, that polarize the cell and initiate directed migration. CD300 family receptors can also modulate these responses.
Adhesion and extracellular matrix interaction
In simple terms: Eosinophils stick to and crawl along surfaces using adhesion molecules.
Following receptor activation, eosinophils undergo integrin-mediated adhesion to endothelial cells and extracellular matrix components. Heparan sulfate proteoglycans on cell surfaces or in the matrix can bind and present CCL26 to CCR3, enhancing chemotaxis. This step is essential for transmigration across vascular endothelium and movement through tissues.
Cytoskeletal rearrangement and cell polarization
In simple terms: The cell changes shape to move forward.
Chemotaxis requires dynamic reorganization of the actin cytoskeleton, leading to formation of a leading edge and a trailing uropod. Rho-family GTPases, including Rac and Rho, coordinate these changes. This polarization enables the eosinophil to move directionally along the chemoattractant gradient.
Directed migration and gradient sensing
In simple terms: The cell moves toward higher concentrations of the chemical signal.
Eosinophils sense shallow gradients of chemoattractants and migrate toward the source. This process involves local activation of PI3K and accumulation of PIP3 at the leading edge, which recruits actin-nucleating proteins. The complement system, particularly C5a, has been shown to induce eosinophil chemotaxis in early studies.
Termination and resolution
In simple terms: The cell stops moving once it reaches the target or the signal fades.
Chemotaxis is terminated by degradation of chemoattractants, receptor desensitization, or negative feedback pathways. Dysregulation of termination can lead to persistent eosinophil accumulation and chronic inflammation. Understanding resolution mechanisms is important for developing therapies that limit eosinophil-driven tissue damage.
Key Genes Involved in GO:0048245 eosinophil chemotaxis
The following genes and proteins are central to eosinophil chemotaxis, based on verified literature and QuickGO annotations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCL11 | Eotaxin-1, chemoattractant for eosinophils via CCR3 | Allergic inflammation models |
| CCL24 | Eotaxin-2, chemoattractant for eosinophils | Eosinophilic esophagitis research |
| CCL26 | Eotaxin-3, chemoattractant; induced by glycolysis | Chronic rhinosinusitis with nasal polyps |
| CCR3 | Primary receptor for eotaxins on eosinophils | Target for anti-eosinophil therapies |
| CD300A | Inhibitory receptor regulating eosinophil chemotaxis | Modulation of allergic responses |
| CD300C | Activating receptor affecting eosinophil functions | Eosinophil effector function studies |
| C5 | Complement component generating C5a | Classical chemotaxis studies |
| C5AR1 | Receptor for C5a on eosinophils | Complement-mediated chemotaxis |
| ITGB1 | Integrin beta-1, mediates adhesion during chemotaxis | Cell migration assays |
| ITGB2 | Integrin beta-2, involved in leukocyte adhesion | Eosinophil transmigration |
| RAC1 | Rho GTPase regulating actin cytoskeleton | Cytoskeletal dynamics in chemotaxis |
| RHOA | Rho GTPase controlling cell contractility | Migration and polarization |
| PIK3CA | PI3K catalytic subunit, generates PIP3 | Gradient sensing |
| AKT1 | Serine/threonine kinase downstream of PI3K | Survival and chemotaxis signaling |
| HSPG2 | Heparan sulfate proteoglycan, binds CCL26 | Modulates chemotaxis |
| VDR | Vitamin D receptor, regulates CCL26 expression | Eosinophilic chronic rhinosinusitis |
| LDHA | Lactate dehydrogenase A, glycolysis enzyme | Glycolysis-induced CCL26 expression |
How Is eosinophil chemotaxis Regulated?
Eosinophil chemotaxis is regulated at multiple levels, including chemoattractant availability, receptor expression, and intracellular signaling. Glycolysis-induced CCL26 expression in nasal polyp fibroblasts is inhibited by vitamin D, thereby impeding eosinophil chemotaxis. Heparan sulfate proteoglycans modulate CCL26-induced chemotaxis by presenting the chemokine to CCR3. CD300 family receptors can deliver inhibitory or activating signals that fine-tune eosinophil migration. Additionally, complement activation generates C5a, a potent chemoattractant. These regulatory mechanisms ensure appropriate eosinophil recruitment while preventing excessive tissue damage.
eosinophil chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCL26 | Chronic rhinosinusitis with nasal polyps | Knockout of CCL26 in nasal polyp fibroblasts |
| CCR3 | Allergic asthma | Knockout mice or CCR3 antagonist studies |
| CD300A | Eosinophilic inflammation | Knockout or overexpression in eosinophil cell lines |
| VDR | Eosinophilic chronic rhinosinusitis | Vitamin D treatment in vitro |
| C5 | Complement-mediated chemotaxis | C5-deficient serum or C5a receptor knockout |
Eosinophilic skin diseases
Eosinophilic skin diseases, including atopic dermatitis and eosinophilic cellulitis, are characterized by eosinophil infiltration into the skin. Chemotaxis of eosinophils toward eotaxins and other chemoattractants is a key pathogenic step. Targeting chemotaxis pathways may reduce skin inflammation.
Chronic rhinosinusitis with nasal polyps
In eosinophilic chronic rhinosinusitis with nasal polyps, glycolysis-induced CCL26 expression promotes eosinophil chemotaxis. Vitamin D inhibits this pathway, suggesting a therapeutic approach. Heparan sulfate also modulates CCL26 activity in this context.
Allergic asthma and parasitic infections
Eosinophil chemotaxis is central to allergic asthma pathogenesis and host defense against helminths. Complement-derived C5a and eotaxins drive eosinophil recruitment to the lungs. Understanding these mechanisms informs biologic therapies targeting eosinophils.
From eosinophil chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate eosinophil chemotaxis? | CRISPR knockout in eosinophil-like cell lines (e.g., HL-60 clone 15) |
| Does a point mutation in CCR3 affect ligand binding? | CRISPR point mutation knock-in in primary eosinophils or cell lines |
| Can a tagged chemokine receptor be used to track trafficking? | Knock-in of fluorescent tag at endogenous locus |
| Does overexpression of CCL26 enhance chemotaxis? | Lentiviral overexpression in fibroblasts or epithelial cells |
| Which genes are essential for chemotaxis in vivo? | CRISPR library screening in mouse models |
| How does heparan sulfate modification affect CCL26 activity? | Knockout of HS-modifying enzymes in cell lines |
How to Study the eosinophil chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell assay | Directed migration toward chemoattractant | Screening inhibitors or gene knockouts |
| Microfluidic gradient | Real-time chemotaxis dynamics | Live-cell imaging of polarization |
| CRISPR library screen | Genes required for chemotaxis | Functional genomics |
| RNA-seq | Transcriptional changes during chemotaxis | Identifying regulated pathways |
| Phosphoproteomics | Signaling events downstream of receptors | Mapping kinase cascades |
| Co-immunoprecipitation | Protein-protein interactions | Receptor complex analysis |
| Flow cytometry | Eosinophil surface marker expression | Phenotyping after gene editing |
In vitro chemotaxis assays
Transwell and Boyden chamber assays are standard for measuring eosinophil chemotaxis toward chemoattractants. These methods quantify directed migration and can be adapted for high-throughput screening. They are used to test inhibitors or genetic modifications.
Live-cell imaging and tracking
Time-lapse microscopy allows visualization of eosinophil polarization and movement in real time. Fluorescently labeled cells can be tracked in microfluidic gradients to assess directionality and speed. This approach provides detailed kinetic data on chemotaxis.
Genetic screening and transcriptomics
CRISPR library screening can identify genes required for eosinophil chemotaxis. RNA-seq of chemotaxing eosinophils reveals transcriptional programs activated during migration. These methods uncover novel regulators and pathways.
Protein interaction and signaling studies
Co-immunoprecipitation and proximity labeling can identify proteins interacting with chemokine receptors during chemotaxis. Phosphoproteomics reveals signaling events downstream of receptor activation. These techniques help map the molecular machinery of chemotaxis.
How CRISPR Can Be Used to Study GO:0048245 eosinophil chemotaxis
Knockout
CRISPR knockout of candidate genes such as CCR3, CD300A, or CCL26 in eosinophil cell lines or primary cells can determine their requirement for chemotaxis. Knockout models are used to validate targets identified in screens.
Point Mutation
Introducing point mutations in chemokine receptors or signaling molecules can dissect specific residues required for ligand binding or downstream signaling. For example, mutating phosphorylation sites in CCR3 may affect desensitization.
Knock-in
Knock-in of fluorescent tags or reporter genes at endogenous loci enables tracking of chemokine receptor trafficking and expression during chemotaxis. This approach preserves native regulation.
Overexpression
Overexpression of chemoattractants like CCL26 or signaling proteins can enhance chemotaxis and model disease states. This is useful for studying gain-of-function mechanisms.
How EDITGENE Supports eosinophil chemotaxis Research
Researchers studying eosinophil chemotaxis-related genes often need to determine whether a candidate gene is causally involved in migration, and CRISPR-based models provide a direct way to test this. EDITGENE offers a suite of services to generate precisely edited cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for eosinophil chemotaxis research.
Frequently Asked Questions About eosinophil chemotaxis
What is eosinophil chemotaxis?
Eosinophil chemotaxis (GO:0048245) is the movement of an eosinophil in response to an external stimulus, typically a chemical gradient.
What genes are involved in eosinophil chemotaxis?
Key genes include CCL11, CCL24, CCL26, CCR3, CD300A, CD300C, C5, C5AR1, ITGB1, ITGB2, RAC1, RHOA, PIK3CA, AKT1, HSPG2, VDR, and LDHA.
How is eosinophil chemotaxis measured?
It is commonly measured using Transwell or Boyden chamber assays, microfluidic gradients, and live-cell imaging.
What diseases involve eosinophil chemotaxis?
Allergic asthma, eosinophilic skin diseases, chronic rhinosinusitis with nasal polyps, and parasitic infections involve eosinophil chemotaxis.
What is the role of CCL26 in eosinophil chemotaxis?
CCL26 (eotaxin-3) is a chemoattractant that binds CCR3 and induces eosinophil migration; its expression can be driven by glycolysis and modulated by heparan sulfate.
How does vitamin D affect eosinophil chemotaxis?
Vitamin D inhibits glycolysis-induced CCL26 expression, thereby impeding eosinophil chemotaxis in chronic rhinosinusitis with nasal polyps.
What are CD300 receptors?
CD300 family receptors regulate eosinophil survival, chemotaxis, and effector functions, with some members being inhibitory and others activating.
Can CRISPR be used to study eosinophil chemotaxis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in chemotaxis.
What is the complement system's role in eosinophil chemotaxis?
Complement component C5a is a classical chemoattractant for eosinophils, and C5 deficiency impairs chemotaxis.
Why is eosinophil chemotaxis important in infection?
Eosinophil chemotaxis is essential for recruiting eosinophils to sites of helminth infection, where they contribute to host defense.
Conclusion
Eosinophil chemotaxis (GO:0048245) is a fundamental biological process that governs eosinophil recruitment in health and disease. Its molecular regulation involves a complex interplay of chemoattractants, receptors, adhesion molecules, and signaling pathways. Dysregulation contributes to allergic and inflammatory disorders, making it a target for therapeutic intervention. CRISPR-based models and advanced screening methods provide powerful tools to dissect the genetic control of eosinophil chemotaxis. EDITGENE offers comprehensive services to support such research, from knockout to library screening.
References
- 1. Dent G. 2014. Eosinophil chemotaxis.. Methods Mol Biol 1178:101-10 PMID: 24986611
- 2. Rani A et al.. 2025. Peptide-based lipid nanodiscs suppress eosinophil recruitment and chemotaxis.. J Control Release 385:114060 PMID: 40701272
- 3. Long H et al.. 2016. Eosinophilic Skin Diseases: A Comprehensive Review.. Clin Rev Allergy Immunol 50(2):189-213 PMID: 25876839
- 4. Rozenberg P et al.. 2018. CD300 family receptors regulate eosinophil survival, chemotaxis, and effector functions.. J Leukoc Biol 104(1):21-29 PMID: 29345367
- 5. Huang W et al.. 2025. Vitamin D impedes eosinophil chemotaxis via inhibiting glycolysis-induced CCL26 expression in eosinophilic chronic rhinosinusitis with nasal polyps.. Cell Commun Signal 23(1):104 PMID: 39985085
- 6. Pum A et al.. 2022. The Role of Heparan Sulfate in CCL26-Induced Eosinophil Chemotaxis.. Int J Mol Sci 23(12) PMID: 35742962
- 7. Ravin KA et al.. 2016. The Eosinophil in Infection.. Clin Rev Allergy Immunol 50(2):214-27 PMID: 26690368
- 8. Kay AB. 1974. Chemotaxis of eosinophil leukocytes in relation to immediate-type hypersensitivity and the complement system.. Antibiot Chemother (1971) 19:271-83 PMID: 4142850
